WFSBP 2019 Preliminary Program

15 WFSBP 2019 Symposia / Preliminary Scientific Program S-01-002 Structural MRI in first-episode psychosis: An interna- tional collaborative mega-analysis of individual adult patient data Brian Hallahan, Ireland S-01-003 Neuroanatomical dysconnectivity in Bipolar Disorder (BD): A graph theory study across three centres Stefani O´Donoghue, USA S-01-004 Classification and clustering of patients with Bipolar Disorder (BD) based on DTI data: Relationship with clinical dimensions Pauline Favre, France T3: ANTIDEPRESSANTS: BASIC/CLINICAL S-02 08:15–09:45 Rapid-acting antidepressants: Current practice, predictive markers and neurobiological mechanisms Chair: Tomi Rantamäki, Finland Co-Chair: Carlos Zarate jr., USA S-02-001 Ketamine as a rapid-acting antidepressant: Where do we stand? Carlos Zarate jr., USA S-02-002 Neurobiological mechanisms associated with rapid anti- depressant responses Todd Gould, USA S-02-003 Ketamine treatment biosignatures and molecular path- ways Christoph W. Turck, Germany S-02-004 No laughing matter: How nitrous oxide helps under- standing rapid antidepressant mechanisms Tomi Rantamäki, Finland T52: SCHIZOPHRENIA AND OTHER PSYCHOSIS: BASIC/CLINICAL S-03 08:15–09:45 Compensatory brain responses in the emergence and development of psychosis Chair: Christos Pantelis, Australia Co-Chair: Lena Palaniyappan, Canada S-03-001 Converging observations of cortical structural reorgani- zation in psychosis Lena Palaniyappan, Canada S-03-002 Brain functional network reorganization related to clini- cal progression in persons at-risk for psychosis Juan Helen Zhou, Singapore S-03-003 Trajectories of brain change in psychosis: Impact of risk and resilience factors Christos Pantelis, Australia S-03-004 Understanding the biological bases of the acute brain response in early psychosis Amanda Lyall, USA T46: PSYCHONEUROIMMUNOLOGY S-04 08:15–09:45 Immune modulation in mood disorders: Rationale and novel treatment options Chair: Bernhard Baune, Australia Co-Chair: Michael Berk, Australia S-09-001 Is there rationale and hope for immune-modifying treatment in mood disorders? Bernhard Baune, Australia S-09-002 Is there clinical trial evidence for anti-inflammatory approaches? Michael Berk, Australia S-09-003 Anti-inflammatory augmentation therapy in depression: The Adelaide PREDDICT study Celia Fourier, Australia S-09-004 Immune-metabolics in mood disorders Roger McIntyre, Canada MON